Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Hypertension 1Glioblastoma 1Cognitive Dysfunction 1Cardiotoxicity 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Exercise 6Transcranial Direct Current Stimulation 4Neuropsychological Tests 4Walking 3Memantine 3Tablets 2Standard of Care 2Patient Reported Outcome Measures 2Methods 2Electroencephalography 2Drug Therapy 2Donepezil 2Cognitive Behavioral Therapy 2mazdutide 1lithium sulfate 1lime 1fasudil 1enzalutamide 1blueberry extract 1beta Carotene 1acetaminophen, aspirin, caffeine drug combination 1XENP 1595 1Vitamin E 1Vitamin D 1Ultraviolet Therapy 1Transcranial Magnetic Stimulation 1Time 1Therapeutics 1Tai Ji 1Surveys and Questionnaires 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cognitive Dysfunction × Ramipril × Clear all
NCT03475186 2026-03-13

Testing Ramipril to Prevent Memory Loss in People With Glioblastoma

Wake Forest University Health Sciences

Phase 2 Completed
75 enrolled 47 charts
CNS

Brain Neoplasms, Glioblastoma, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡